Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/335537
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study |
Autor: | Español-Rego, Marta; Fernández-Martos, Carlos; Elez, Elena; Pedrosa, Leire; Rodríguez, Núria; Ruiz‑Casado, Ana; Pineda, Estela; Rodríguez, Núria; Cid, Joan; Cabezón, Raquel; Oliveres, Helena; Lozano, Miquel; Ginés, Angels; García‑Criado, Ángeles; Ayuso, Juan Ramón; Pagés, Mario; Cuatrecasas, Miriam; Torres, Ferrán; Thomson, Timothy M. CSIC ORCID ; Cascante, Marta CSIC ORCID; Benítez-Ribas, Daniel | Palabras clave: | Vaccines Metabolism Resistance |
Fecha de publicación: | 2023 | Editor: | Springer | Citación: | Cancer Immunology, Immunotherapy 72: 827-840 (2023) | Resumen: | [Background]: Immune check-point blockade (ICB) has shown clinical beneft in mismatch repair-defcient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-profcient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic efects. [Methods]: This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor efects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efcacy of the combination. The primary end-point was 40% progressionfree survival at 6 months with a 2 Simon Stage. [Results]: A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design frst-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1–5.3 months] and overall survival was 12.2 months [3.2–23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted signifcant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, infammation and oxidative stress pathways. [Conclusions]: The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the frst-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapyinduced tumor vulnerabilities. | Versión del editor: | http://dx.doi.org/10.1007/s00262-022-03283-5 | URI: | http://hdl.handle.net/10261/335537 | DOI: | 10.1007/s00262-022-03283-5 | Identificadores: | issn: 0340-7004 e-issn: 1432-0851 |
Aparece en las colecciones: | (IBMB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
A_Phase_I‑II_multicenter_Español_Art2023.pdf | 3,33 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
6
checked on 03-may-2024
WEB OF SCIENCETM
Citations
4
checked on 28-feb-2024
Page view(s)
28
checked on 08-may-2024
Download(s)
16
checked on 08-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons